Amifampridine

Drug Profile

Amifampridine

Alternative Names: 3,4-DAP; 3,4-DAP phosphate; 3,4-Diaminopyridine; Amifampridine phosphate; Firdapse; Zenas

Latest Information Update: 21 Mar 2017

Price : $50

At a glance

  • Originator Assistance Publique Hopitaux de Paris
  • Developer BioMarin Pharmaceutical; Catalyst Pharmaceutical Partners; Fondazione Istituto Neurologico Carlo Besta
  • Class Aminopyridines; Small molecules
  • Mechanism of Action Acetylcholine stimulants; Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lambert-Eaton myasthenic syndrome; Myasthenia gravis; Congenital myasthenic syndromes
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Lambert-Eaton myasthenic syndrome
  • Preregistration Congenital myasthenic syndromes
  • Phase II/III Myasthenia gravis

Most Recent Events

  • 16 Mar 2017 Efficacy data from phase II/III trial in Myasthenia gravis released by Catalyst Pharmaceuticals
  • 15 Dec 2016 Catalyst Pharmaceuticals enrols first patient in the phase III LEMS-003 trial for Lambert-Eaton myasthenic syndrome in USA
  • 01 Nov 2016 Catalyst Pharmaceuticals initiates a phase III trial in Lambert-Eaton myasthenic syndrome in USA (NCT02970162)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top